Compare FTAI & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTAI | DGX |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5B | 23.2B |
| IPO Year | 2014 | 1996 |
| Metric | FTAI | DGX |
|---|---|---|
| Price | $189.52 | $238.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $274.67 | $214.38 |
| AVG Volume (30 Days) | ★ 1.2M | 751.0K |
| Earning Date | 04-29-2026 | 04-21-2026 |
| Dividend Yield | 0.75% | ★ 1.82% |
| EPS Growth | ★ 1537.50 | 13.78 |
| EPS | 2.42 | ★ 5.08 |
| Revenue | $2,507,409,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $32.73 | $7.53 |
| Revenue Next Year | $51.41 | $3.77 |
| P/E Ratio | $78.55 | ★ $47.30 |
| Revenue Growth | ★ 44.53 | 11.78 |
| 52 Week Low | $148.43 | $171.18 |
| 52 Week High | $323.51 | $247.19 |
| Indicator | FTAI | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 64.91 |
| Support Level | $179.11 | $190.40 |
| Resistance Level | $232.85 | N/A |
| Average True Range (ATR) | 9.19 | 4.14 |
| MACD | -1.81 | -0.82 |
| Stochastic Oscillator | 7.13 | 71.00 |
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.